Please login to the form below
Affimed
This page shows the latest Affimed news and features for those working in and with pharma, biotech and healthcare.
Xencor’s Novartis-partnered bispecific on hold after patient deaths
In this case however the concerns were about liver toxicity. A few weeks earlier a trial of Affimed’s CD3- and CD19-targeting bispecific AFM11 in non-Hodgkin’s lymphoma was
Latest news
-
Affimed rockets on $5bn-plus Roche immuno-oncology deal
German biotech Affimed saw its share price more than triple yesterday after Roche’s Genentech agreed an alliance to discover new cancer immunotherapies with a jaw-dropping milestone figure. ... Roche is paying $96m in upfront and near-term funding
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Novo Nordisk growth takes a hit with China deal
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Merck enters agreement with Hanmi for investigational NASH drug
- Booster plans expanded to combat Omicron
- US regulators set to approve oral antiviral against COVID-19
- What does the future hold for Light-chain Amyloidosis?
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
PMHub
11 London
The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...
Latest intelligence
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
